24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Biopharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:16
"We see the biggest opportunities in residential construction"
15:05
"Our goal is to produce clean, affordable energy that supports the economy"
14:52
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
12:59
"We’re effectively democratizing access to computing power through our platform"
More stories
Buzz
Most popular
Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
4
Former Snyk founder Guy Podjarny secures $125M for AI-powered software startup Tessl
5
Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline
More news
Biopharma
6 stories about Biopharma
Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund
16.08.22
|
CTech
The trial will study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa
SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF
13.05.21
|
Meir Orbach
The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research
Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria
26.01.21
|
Meir Orbach
The novel agents developed by Omnix are designed as an alternative to classical antibiotics
Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering
09.04.19
|
CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
24.07.18
|
Lilach Baumer
The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
RedHill's Public Offering Spooks Investors, Sends Stock Down
09.11.17
|
Dror Reich
The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close
Please ensure Javascript is enabled for purposes of
website accessibility